Emerald Advisers Inc. PA lowered its stake in Ziopharm Oncology Inc. (NASDAQ:ZIOP) by 0.2% during the second quarter, according to its most recent filing with the SEC. The firm owned 551,521 shares of the biotechnology company’s stock after selling 1,230 shares during the period. Emerald Advisers Inc. PA’s holdings in Ziopharm Oncology were worth $3,028,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Emerald Mutual Fund Advisers Trust boosted its position in Ziopharm Oncology by 3.1% in the second quarter. Emerald Mutual Fund Advisers Trust now owns 596,693 shares of the biotechnology company’s stock valued at $3,276,000 after buying an additional 17,929 shares during the last quarter. Palo Capital Inc. purchased a new position in Ziopharm Oncology during the second quarter valued at $350,000. Fox Run Management L.L.C. purchased a new position in Ziopharm Oncology during the second quarter valued at $133,000. Creative Planning boosted its position in Ziopharm Oncology by 185.1% in the second quarter. Creative Planning now owns 30,864 shares of the biotechnology company’s stock valued at $169,000 after buying an additional 20,040 shares during the last quarter. Finally, Royal Bank of Canada boosted its position in Ziopharm Oncology by 6.4% in the first quarter. Royal Bank of Canada now owns 16,189 shares of the biotechnology company’s stock valued at $120,000 after buying an additional 974 shares during the last quarter. Hedge funds and other institutional investors own 44.95% of the company’s stock.
Ziopharm Oncology Inc. (NASDAQ:ZIOP) traded up 1.25% during mid-day trading on Friday, reaching $5.69. The company had a trading volume of 986,285 shares. Ziopharm Oncology Inc. has a 12-month low of $4.45 and a 12-month high of $14.93. The stock’s market capitalization is $742.52 million. The stock has a 50 day moving average price of $5.47 and a 200-day moving average price of $6.33.
Ziopharm Oncology (NASDAQ:ZIOP) last posted its quarterly earnings data on Tuesday, August 9th. The biotechnology company reported ($1.01) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.11) by $0.90. Ziopharm Oncology had a negative return on equity of 100.01% and a negative net margin of 2,292.26%. The business earned $1.70 million during the quarter, compared to analysts’ expectations of $1.52 million. During the same period in the prior year, the firm posted ($0.11) EPS. The firm’s revenue for the quarter was up 525.0% on a year-over-year basis. Equities analysts anticipate that Ziopharm Oncology Inc. will post ($1.34) EPS for the current fiscal year.
Several research analysts have weighed in on the company. Zacks Investment Research upgraded Ziopharm Oncology from a “hold” rating to a “buy” rating and set a $6.50 price objective on the stock in a research report on Tuesday, August 16th. Griffin Securities reissued a “buy” rating and set a $21.00 target price on shares of Ziopharm Oncology in a report on Monday, August 15th. Wells Fargo & Co. raised Ziopharm Oncology from an “underperform” rating to a “market perform” rating in a report on Wednesday, August 10th. Finally, Mizuho reissued a “neutral” rating and set a $5.00 target price (down from $7.00) on shares of Ziopharm Oncology in a report on Monday, July 18th. Four equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $9.75.
Ziopharm Oncology Company Profile
ZIOPHARM Oncology, Inc is a biopharmaceutical company. The Company is seeking to acquire, develop and commercialize, on its own or with partners, a portfolio of cancer therapies through synthetic immuno-oncology. Its clinical-stage product candidate, Ad-RTS-IL-12, is used with the oral activator veledimex.
Want to see what other hedge funds are holding ZIOP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ziopharm Oncology Inc. (NASDAQ:ZIOP).
Receive News & Ratings for Ziopharm Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ziopharm Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.